The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
Open accessAbstract
Background: Statins preferentially promote tumor-specific apoptosis by depleting isoprenoid such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. However, statins have not yet been approved for clinical cancer treatment due, in part, to poor understanding of molecular determinants on statin sensitivity. Here, we investigated the potential of statins to elicit enhanced immunogenicity of KRAS-mutant (KRAS mut) tumors. Methods: The immunogenicity of treated cancer cells was determined by western blot, flow cytometry and confocal microscopy. The immunotherapeutic efficacy of mono or combination therapy using statin was assessed in KRAS mut tumor models, including syngeneic colorectal cancer and genetically engineered lung and pancreatic tumors. Using NanoString analysis, we analyzed how statin influenced the gene signatures associated with the antigen presentation of dendritic cells in vivo and evaluated whether statin could induce CD8+ T-cell immunity. Multiplex immunohistochemistry was performed to better understand the complicated tumor-immune microenvironment. Results: Statin-mediated inhibition of KRAS prenylation provoked severe endoplasmic reticulum (ER) stress by attenuating the anti-ER stress effect of KRAS mutation, thereby resulting in the immunogenic cell death (ICD) of KRAS mut cancer cells. Moreover, statin-mediated ICD enhanced the cross-priming ability of dendritic cells, thereby provoking CD8+ T-cell immune responses against KRAS mut tumors. Combination therapy using statin and oxaliplatin, an ICD inducer, significantly enhanced the immunogenicity of KRAS mut tumors and promoted tumor-specific immunity in syngeneic and genetically engineered KRAS mut tumor models. Along with immune-checkpoint inhibitors, the abovementioned combination therapy overcame resistance to PD-1 blockade therapies, improving the survival rate of KRAS mut tumor models. Conclusions: Our findings suggest that KRAS mutation could be a molecular target for statins to elicit potent tumor-specific immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This chemopreventive effect demonstrates that mevalonate pathway inhibition can block KRAS-driven tumorigenesis at early stages, suggesting potential applications in high-risk populations.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Nam et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The simvastatin effect in the CT26 murine KRASG12D cell line was reversed by the addition of mevalonate pathway metabolites involved in prenylation, FPP, and GGPP, supporting the idea that simvastatin acts by blocking KRAS protein prenylation.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Nam et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, the only KRAS mutant lines without a statistically significant better response to simvastatin were those that also had BRAF mutations.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Nam et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“The simvastatin + oxaliplatin group also had infiltrates with more CD8+ T-cells than the other groups (Nam et al., 2021).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Nam et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Nam et al. reported greater sensitivity in KRAS-mutant compared with wild-type cancers”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Nam et al., 2021
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 1×
“13 This evidence led us to hypothesize that statin could increase the immunogenicity of KRAS mut cancer cells through severe ER stress, resulting in the activation of APC-mediated T-cell immunity.”
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 6×
“20 We found that CT26 cells pretreated with simvastatin were readily engulfed by BMDMs and BMDCs (figure 3A,B), and that FPP impaired such effects (figure 3A,B), indicating that statin- induced-FPP depletion in KRAS mut tumor cells boosted cancer cell clearance.”
InfluentialThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664 · cited 1×
“28 Oxaliplatin is a first-line chemotherapeutic agent for colorectal, non- small-cell lung, and pancreatic cancers, which are tumors frequently exhibiting KRAS mutations.”
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349 · cited 1×
“Consistent with our Fluorescence-activated cell sorting (FACS) results, the combination therapy significantly increased CD8+ T cells in the TME (figure 6A).”
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173 · cited 1×
“To better understand the complicated tumor-immune microenvironment, we performed a multiplex IHC on the treated tumor tissues from the CT26 syngeneic tumor model.”
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 1×
“Importantly, the ternary combination treat-ment of simvastatin, oxaliplatin, and anti-PD-1 antibodies dramatically suppressed tumor growth and improved the survival rate of CT26 tumor-bearing mice (figure 6F,G).”
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Cited by
Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer
Morofuji, Y., Nakagawa, S., Ujifuku, K., Fujimoto, T., Otsuka, K., Niwa, M., & Tsutsumi, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020151 · Cited by 184
“Several previous reports have indicated that statin-mediated Ras suppression regulates cellular proliferation and cell death, consequently leading to an antitumor effect [38,39].”
BackgroundYuan, Y., Li, P., Li, J., Zhao, Q., Chang, Y., & He, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01759-7 · Cited by 126
“313 317 Despite preclinical and epidemiological data indicating that statins may have antitumour properties, clinical trial results show that statins exert varying therapeutic effects on different malignancies.”
BackgroundStatin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Kansal, V., Burnham, A. J., Kinney, B. L. C., Saba, N. F., Paulos, C. M., Lesinski, G. B., Buchwald, Z. S., & Schmitt, N. C. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005940 · Cited by 118
Lipid metabolism reprogramming of CD8+ T cell and therapeutic implications in cancer
Wang, R., Liu, Z., Fan, Z., & Zhan, H. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216267 · Cited by 86
Yang, Y., Zhang, H., Huang, S., & Chu, Q. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020709 · Cited by 83
“Statins can provoke the CD8+ T-cell immune response to KRAS-mutant tumors, and increase the sensitivity to PD-1 ICIs when combined with oxaliplatin [99].”
Background
Metadata
- Authors
- Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., Han, J., Woo, J., Cho, Y., Jeong, C., Park, S.-Y., Roberts, T. M., Cho, Y. B., & Kim, I.-S.
- Affiliations
- Harvard University (US)
- Korea University Anam Hospital (KR)
- Samsung Medical Center (KR)
- Korea University (KR)
- Korea Institute of Science and Technology (KR)
- Kyung Hee University (KR)
- Dongguk University (KR)
- Corresponding author
- Kim, Seohyun
- Cho, Yong Beom
- Kim, In-San
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-07
- Volume
- 9
- Issue
- 7
- Pages
- e002474
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8327837
- OpenAlex
- W3183405237
- Cited by
- 82
- References
- 49
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 12 · 2023: 19 · 2022: 15 · 2021: 5
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- KU-KIST Graduate School of Conversing Science and Technology Program
- the KIST Institutional Program
- Ministry of Science and ICT (2020R1C1C1003539, 2017R1A3B1023418)
- Korea Health Industry Development Institute (HI19C0753)
- SMC-KIST Collaborative Research Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- statins, KRAS mutation, Ras prenylation, endoplasmic reticulum stress, immunogenic cell death, cancer immunotherapy, CD8+ T cell immunity, anti-PD-1 resistance, tumor immune microenvironment, colorectal cancer, lung cancer, pancreatic cancer, farnesyl pyrophosphate, geranylgeranyl pyrophosphate
- MeSH terms
- Animals, Humans, Male, Mutation, Transfection, Proto-Oncogene Proteins p21(ras), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mice, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. https://app.cochat.ai/papers/10.1136/jitc-2021-002474
- The paper
- Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., Han, J., Woo, J., Cho, Y., Jeong, C., Park, S.-Y., Roberts, T. M., Cho, Y. B., & Kim, I.-S. (2021). Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002474
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.